Name | N-(1,3-dihydroxyoctadec-4-en-2-yl)hexadecanamide |
---|---|
Synonyms |
C16 CERAMIDE
N-(hexadecanoyl)-sphing-4-enine N-Palmitoyl-D-sphingosine N-PALMITOYL-D-SPHINGOSINE C16-ceramide N-Palmitoyl-D-erythro-sphingosine Palmitoyl ceramide N-Hexadecanoyl-D-sphingosine |
Description | C16-Ceramide is a natural small molecule activating p53 through the direct and selective binding[1]. |
---|---|
Related Catalog | |
Target |
Human Endogenous Metabolite |
In Vitro | C16-Ceramide interacts with p53 within its core domain. p53 forms complex with natural C16-Ceramide in the cell[1]. C16-Ceramide (2.5-50 μM; 0-48 h) strongly decreased HCT116 cell viability in a time- and concentration-dependent manner[2]. C16-Ceramide (12 μM; 48 h) induces apoptosis through Btf (Bcl-2-associated transcription factor) in HCT116 cells[2]. C16-ceramide (12 μM; 0-6 h) and Btf expression up-regulate p53 and BAX expression. C16-ceramide down-regulates Mdm2 expression via Btf[2]. Cell Viability Assay[2] Cell Line: HCT116 cells Concentration: 2.5, 5, 10, 12, 20, 50 µM Incubation Time: 0-48 h Result: Strongly decreased cell viability in a time- and concentration-dependent manner. Western Blot Analysis[2] Cell Line: HCT116 cells Concentration: 12 μM Incubation Time: 1, 3 and 6 h Result: Increased PARP cleavage, decreased pro-caspase 3. Decreased the levels of stratifin and stathmin, increased the expression of prohibitin and Btf. RNAi-mediated Btf depletion alsopartially inhibited BAX expression after the treatment. Significantly decreased luciferase activity and Mdm2 protein expression levels. |
Density | 0.919g/cm3 |
---|---|
Boiling Point | 675.396ºC at 760 mmHg |
Melting Point | 94-95ºC |
Molecular Formula | C34H67NO3 |
Molecular Weight | 537.90100 |
Flash Point | 362.267ºC |
Exact Mass | 537.51200 |
PSA | 69.56000 |
LogP | 9.95390 |
Vapour Pressure | 0mmHg at 25°C |
Index of Refraction | 1.48 |
Storage condition | −20°C |
Water Solubility | Soluble in DMF at 0.15mg/ml |